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Abstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare 
lymphoproliferative disorder which can present as an indolent or as an aggressive process involv-
ing skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical 
medications and phototherapy. If there is progression despite application of these treatments, 
or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, 
rexinoids, biologic response modiﬁ  ers are often necessary. Consequently, patients are often 
treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak®) is a targeted 
immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. 
In addition to its unique mechanism of action, DD has a toxicity proﬁ  le which does not overlap 
with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly 
susceptible to treatment with this agent. This review will describe the development DD, its 
proposed mechanism of action, the clinical trials which identiﬁ  ed its utility in the treatment of 
CTCL/MF, the common toxicities encountered with this agent, and the management of these 
toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data 
suggesting potential combination therapies employing this novel agent will be discussed.
Keywords: T-cell lymphoma, mycosis fungoides, immunotoxin, cytokine therapy, denileukin 
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Introduction
Cutaneous T-cell lymphomas (CTCL) represent less then 3% of non-Hodgkin’s 
lymphomas (Gemmill 2006). Surveillance Epidemiology and End Results program 
(SEER) data for CTCL in the US from 1973 to 2002 have shown an overall annual 
age adjusted incidence of 6.4 per million persons (Criscione and Weinstock 2007). 
When compared to prior SEER data, this represents a doubling of the incidence, with 
higher numbers among African Americans and among men. It is seen predominately 
in the ﬁ  fth and sixth decades of life (Habermann and Pittelkow 2004).
T-cell lymphomas have been extensively sub-classiﬁ  ed (see Table 1) (Willemze 
et al 2005). Mycosis fungoides represents the largest subgroup; it typically has an 
indolent course with stereotypical skin eruptions that produce plaques, patches, papules, 
erythema, alopecia, and/or tumors. The typical skin lesions are often confused with 
more common diagnoses including psoriasis, fungal infections, and eczema (Hoffman 
et al 2005). The natural history of this disorder is usually characterized by progressive 
phases. The initial stages usually consist of ﬂ  at erythematous patches. Eventually 
the patches evolve into more inﬁ  ltrating plaques with discrete borders. These ﬁ  ndings 
are usually asymmetrically distributed and involve areas where there is little exposure 
to sun. In later stages there is the development of tumor lesions and erythroderma 
in addition to the plaques and patches (Paulli and Berti 2004). The characteristic 
histological ﬁ  nding is of epidermal inﬁ  ltrates with atypical small- to medium-sized 
T-lymphocytes with cerebriform nuclei. Immunophenotypically, these cells express Biologics: Targets & Therapy 2008:2(4) 718
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CD4+, CD45RO+, and CD3+ markers. A hallmark of the 
malignant phenotype is the loss of CD5, CD7, CD8, and 
CD26 antigens. Overall the 5-year survival approaches 88% 
(Willemze et al 2005). Sezary syndrome is a more aggressive 
disease which typically includes the ﬁ  ndings of erythroderma, 
lymphadenopathy, and peripheral circulating lymphoma 
cells (Rosen and Querfeld 2006). With worsening and more 
advanced disease states, patients experience increasing pain, 
pruritus, cutaneous and systemic infections, disﬁ  gurement, 
and visceral involvement. Staging for CTCL is based on the 
tumor, lymph node, and metastasis (TNM) system. In recent 
years an additional category for hematological involvement 
has been incorporated (TNMB) (see Table 2). An overall 
stage (IA-IVB) can be applied from the TNMB system 
(Scarisbrick 2006). Prognosis is related to the extent of skin 
lesions with a higher T stage corresponding to a reduction in 
survival (Zackheim et al 1999) as well as to TNM groupings 
(Kim et al 2003). Standard treatments for localized disease 
have usually included topical nitrogen mustard, total skin 
electron beam therapy, and phototherapy. For more advanced 
disease states interferon, retinoids, extracorporeal photother-
apy and systemic chemotherapy have been employed. The 
results of treatment of advanced CTCL have been disappoint-
ing with a high incidence of relapsed disease and treatment-
related adverse effects. In addition, since the majority of 
patients with limited disease have relatively good prognosis, 
any treatment that causes excessive myelosuppression or 
immunosuppression would be undesirable. Furthermore, it 
has been proposed that preservation of immune function, 
particularly CD8+ lymphocytes correlates with improved 
survival in CTCL (Abeni et al 2005). These observations 
stress the need for novel agents that can target this disease 
where traditional treatments have fallen short.
Denileukin diftitox (DD) or DAB389IL-2 (Ontak®; 
Eisai, Inc., Woodcliff Lake, NJ, USA) is a fusion 
protein in which the receptor binding domain of 
diphtheria toxin (DT) has been exchanged for that of the 
interleukin-2 (IL-2) molecule. Because of the speciﬁ  city of 
the IL-2 domain, the DT mediated cytotoxic activity will 
predominately affect cells that express the IL-2 receptor 
(IL-2R). The IL-2 receptor is selectively expressed on 
activated T-lymphocytes, B-cells, and natural killer 
(NK) cells. It has been shown that IL-2 fusion toxin is 
cytotoxic against in vitro T-cell lines (Williams et al 
1987; Kiyokawa et al 1989). It has been estimated that 
approximately 50% of CTCL cases express the IL-2R as 
demonstrated by immunohistochemical staining (Nichols 
et al 1997).
Mechanism of action
The IL-2 receptor has been classiﬁ  ed into three subtypes 
based on their afﬁ  nity for IL-2. Each subtype is composed of 
a combination of subunits: alpha (CD25, p 55), beta (CD122, 
p 75), and gamma (CD132, p 64) subunits. The low afﬁ  nity 
receptor consists of the IL-2R-α/γ (CD25, CD132) subunits 
that bind to IL-2 but do not cause internalization or activation. 
In contrast, the intermediate and high afﬁ  nity receptors that 
are composed of IL-2R-β/γ (CD122, CD132) and Il-2R-α/β/γ 
(CD25, CD122, CD133) subunits, respectively, both cause 
internalization and signal transduction (Re et al 1996). The 
presence of the β and γ (CD122, CD132) subunits is essential 
for sensitivity and internalization, respectively, of the fusion 
toxin. If they are lacking from the tumor cell, DD will be 
ineffective.
After DD binds to the IL-2 receptor, it is taken up by the 
cell via receptor mediated endocytosis. Once internalized, 
acidiﬁ  cation occurs; this is vital for the translocation of 
DT fragment A into the cytoplasm (Bacha et al 1988). 
The proposed mechanism of action is that the internalized 
fragment A catalyzes the cleavage of nicotinamide adenine 
dinucleotide (NAD) to nicotinamide resulting in a transfer of 
ADP to elongation factor-2 (EF-2). This ADP-ribosylation of 
EF-2 causes inhibition of mRNA prolongation and ultimately 
inhibition of protein synthesis.
DAB489-IL-2 clinical trials
The ﬁ  rst form of a DT fusion protein was DAB486-IL-2 
which entered clinical trials in the early 1990s. A phase I 
Table 1 Classiﬁ  cation of the common cutaneous lymphomas, 
associated frequency, and 5-year disease speciﬁ  c survival
WHO-EORTC classiﬁ  cation Frequency % 5-year survival %
Cutaneous T-cell lymphoma
 Mycosis  fungoides 44 88
 Folliculotropic  MF 4 80
 PCALCL 8 95
 Lymphomatoid  papulosis 12 100
 Sezary  syndrome 3 24
Cutaneous B-cell lymphoma
 PCMZBL 7 99
 PCFCL 11 95
 PCDLBCL,  LT 4 55
Adapted from Willemze et al 2005.
Abbreviations: PCALCL, primary cutaneous anaplastic large cell lymphoma; PCMZBL, 
primary cutaneous marginal zone B-cell lymphoma; PCFCL, primary cutaneous 
follicular center lymphoma; PCDLBCL, LT, primary cutaneous diffuse large B-cell cell 
lymphoma, leg type.Biologics: Targets & Therapy 2008:2(4) 719
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dose escalation trial in 18 previously treated patients with 
various hematological malignancies (including 1 patient 
with CTCL) showed a response rate of approximately 17%, 
1 with complete and 2 with partial responses (LeMaistre 
et al 1992). All the patients in this study had tumors that 
expressed the p 55 subunit. The maximal treatment dose 
was limited to 0.1 mg/kg/day secondary to transient hepatic 
transaminase elevation. Fever was associated with the admin-
istration, which was treated effectively with acetaminophen. 
No opportunistic infections were observed following this 
treatment. Prior to receiving the drug, four patients had 
positive antibodies against DT and two additional patients 
had evidence of anti-IL-2 antibodies. After treatment 
many of the patients were found to have antibodies against 
DAB486-IL-2, DT, and IL-2. Regardless of these ﬁ  ndings, 
an anti-tumor effect was not compromised in the majority 
of the patients who showed an increase in the titer of these 
antibodies.
Hesketh and colleagues later explored the role of 
DAB486-IL-2 in cutaneous T-cell lymphoma in previously 
treated patients with refractory disease (Hesketh et al 1993). In a 
limited phase one trial, using 2 dose schedules, 3 out of 5 patients 
demonstrated a signiﬁ  cant response. The range of responses 
included complete resolution of stage Ia disease for greater 
than 33 months, partial response in a CTCL/Sezary syndrome 
patient with marked improvement in skin manifestations and 
Sezary cell count, and a stage IIa patient who had a partial 
response with improvement of skin plaques. Overall, both 
treatment doses were well tolerated. As seen in the study of 
LeMaistre et al (1993), transient asymptomatic elevation of 
liver transaminases were noted. Other side effects included 
mild hypotension, ﬂ  u-like symptoms, myalgias, fever, chills, 
and vomiting. All patients had a documented infection during 
the treatment course (including 1 death); however, it is not clear 
if this was associated with this medication or represented the 
natural history of CTCL patients. While all the patients with 
a signiﬁ  cant response had evidence of IL-2R expression, the 
heterogeneity of this expression was striking and ranged from 
40% to less than 5% in the analyzed samples. This ﬁ  nding 
may be related to the limitations of the immunohistochemical 
assays employed, since this assay only recognized the low-
afﬁ  nity IL-2R subunit. In addition, the authors point out that 
in CTCL there may be a background of activated lymphocytes 
that express IL-2R and may contribute to false positive result. 
Similar to the ﬁ  ndings in the prior study, and contrary to in vitro 
assays, the presence antibodies against DAB486-IL-2, DT, or 
IL-2 did not inﬂ  uence the rate of response to treatment.
Prior in vitro observations suggest that cytotoxicity 
of DAB486-IL-2 is not only dependent on the dose but 
also on the duration of ligand–receptor interaction. A trial 
that investigated a longer infusion time of 90 minutes in 
patients who had prior treatment attempted to address this 
issue (LeMaistre et al 1993). This trial involved 23 patients 
including 3 with CTCL. Conﬁ  rmation of expression of CD25 
(p55) was made in 11 of the 23 patients, with 4 patients 
being negative and the results for another 8 patients being 
unknown. While the longer infusions were well tolerated, and 
achieved serum levels of DAB486-IL-2 which were known 
to be active in vitro, this treatment schedule failed to show a 
statistical difference in the area under the concentration curve 
and the clearance of ligand–toxin complex. These studies of 
longer infusion times did, however, conﬁ  rm prior phase one 
results; clinical responses were seen in a total of 6 patients 
(4 patients had a reduction of 25% to 50% in disease that 
lasted approximately 4 weeks). All of the responders were 
CD25 (p55) positive. Of note, 2 of the 3 CTCL patients had a 
partial and minimal response, with the third having stable dis-
ease. A major limitation of this as well of other early studies is 
the inability to determine if the detection of CD25 represents 
the presence of high-afﬁ  nity or low afﬁ  nity IL-2R.
Another trial involving 20 patients in a dose-escalating 
60-minute infusion of DAB486-IL2 showed no signiﬁ  cant 
Table 2 TNMB staging system for cutaneous T-cell lymphoma
Tumor stage
 T1 Patches/plaques 10% BSA




  N0 No palpable LN, no histological 
involvement
  N1 Palpable LN, no histological 
involvement
 N2 No palpable LN, + histological 
involvement
 N3 Palpable LN, + histological 
involvement
Metastatic stage
  M0 No visceral disease
 M1 Visceral  disease
Blood stage
  B0 No hematological involvement
 B1 Sezary count 5% of peripheral 
blood lymphocytes
Adapted from Scarisbrick 2006.
Abbreviations: BSA, body surface area; LN, lymph node.Biologics: Targets & Therapy 2008:2(4) 720
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pharmacokinetic difference compared to other trials. 
Interestingly, 10 patients had CTCL; 1 of these patients 
with Sezary syndrome had a partial response and 4 others 
had mixed responses with some skin lesions that resolved 
while other lesions evolved or remained stable (Kuzel et al 
1993). As in the prior studies, DT, or IL-2 antibody titers 
of the subjects were measured both pre- and post-treatment. 
While this study did not draw any speciﬁ  c conclusions about 
the effect of these antibodies, the authors suggested that a 
less immunogenic fusion peptide might be subject to less 
antibody-mediated neutralization.
A phase II study involving 14 patients with CTCL again 
proved the clinical efﬁ  cacy of this drug (Foss et al 1994). In 
this report, 1 of 14 patients had a partial response and 2 had 
a major biologic response (deﬁ  ned as improvement in skin 
lesions but without clearance of neoplastic cells from the 
peripheral blood). As in the other studies, the presence of anti 
DT antibodies did not preclude response to treatment, and 
presence of CD25 did not differentiate between responders 
and non-responders.
DAB389-IL-2 clinical trials
Modiﬁ  cations of DAB486-IL-2 with an internal in-frame 
deletion of 97 amino acids from the receptor binding domain 
produced a fusion protein with a 5-fold greater afﬁ  nity for 
target cells. This modiﬁ  cation also yielded an approximately 
10-fold increase in the potency of the molecule, and an overall 
increase in its half life (Williams et al 1990; Lemaistre et al 
1998). This new fusion toxin was named DAB389-IL-2 and 
later became known as DD.
Saleh and colleagues initiated the ﬁ  rst phase I/II clinical 
trial evaluating the efﬁ  cacy of this new formulation included 
35 patients with CTCL. Of this group, there was a 34% 
response rate over various dose ranges with 5 complete and 7 
partial responses (Saleh et al 1998). In addition, many of the 
patients reported signiﬁ  cant improvement in their symptoms. 
Common side effects that were encountered included fever 
and chills, transient elevation in hepatic transaminases, and 
nausea.
In a subsequent smaller phase II trial, 4 heavily pretreated 
patients with CTCL received 9 or 18 μg/kg DAB389IL-2 
daily for 5 days followed another course 21 days later for a 
total of 8 cycles (Duvic et al 1998). These patients had skin 
plaques which involved the mean of 36% of the body surface 
area. Three of the patients received the 18 μg/kg dose and 
1 patient received the 9 μg/kg dose. One patient achieved 
a complete pathological response, another patient had a 
complete clinical response, and the 2 remaining patients 
had partial responses. The duration of response ranged from 
5 to greater than 11 months, and the majority of reduction 
in disease burden was noted after the second cycle. As in 
previous trials, there was no relationship noted between 
the presence of IL-2Rα and clinical response. Importantly, 
patients reported marked improvement in symptoms and 
quality of life with some patients returning to work.
In a larger phase I dose-escalating trial, 73 patients with 
various hematological malignancies were enrolled to receive 
up to 8 courses of DAB389-IL-2 given as a 5-minute infusion 
for 5 days with additional treatments every 21 days. In order 
to be enrolled in this trial, all tumors required expression, via 
immunohistochemical assay, of either the CD25 or CD122 
subunits of IL-2 receptor. Of the 35 patients enrolled with 
CTCL, 30 had mycosis fungoides, 4 patients had large-cell 
CTCL, and 1 patient had a peripheral T-cell lymphoma. 
The stages of disease ranged from stage IA to stage IVB, 
with the majority of patients being heavily pretreated. Of 
the CTCL patients, 5 patients had complete and 8 patients 
had partial responses (overall RR 37%; 95% CI 21%–53%) 
(LeMaistre et al 1998; Saleh et al 1998). The median time to 
response was 2 months with a median duration of response 
of approximately 10 months. Dose-limiting toxicity was 
seen at 31 μg/kg/day dose for 5 days and included asthenia, 
fever, nausea, and vomiting as the predominant symptoms. 
Unlike DAB486-IL-2, changes in liver function test were 
not dose limiting. Interestingly, some of the patients 
with CTCL were found to have edema, hypotension, and 
hypoalbuminemia, suggestive of a capillary leak-syndrome. 
As seen with the DAB486-IL-2 studies, the presence of 
antibodies to DT or DAB389IL-2 did not prevent a treatment 
response. Of note, there was no correlation between the 
expressions of either of the subunits and a clinical response. 
An association may have been seen if CD132 was assayed 
as this has subsequently been shown to be necessary for a 
response (Re et al 1996).
The pivotal phase III trial, a randomized, blinded, 
multicenter study to determine the efﬁ  cacy, pharmacokinetics, 
and toxicity of 2-dose regimens of DD in patients who 
received prior treatment for stage IB to IVA CTCL, was 
reported by Olsen and colleagues. In order to be included, 
participants had to have greater than 20% of lymphocytes 
within the skin biopsy site stain positive for CD25. Patients 
were randomly assigned to receive either a 9 or 18 μg/kg/day 
dose for 5 consecutive days; treatment was repeated every 
21 days for up to 8 cycles. There was further randomization 
of the population into those with IIA and IIB disease. 
At the conclusion of the study, 71 patients were enrolled; Biologics: Targets & Therapy 2008:2(4) 721
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68% of these patients had stage IIB or more advanced disease. 
The study yielded an approximately 30% response rate 
(CI, 18%–41%) with 10% of patients exhibiting a complete 
response. The overall response rate between the 2 dosage 
groups did not reach statistical difference; however there was 
a trend to superiority in efﬁ  cacy of the higher dose in patients 
with greater than stage IIB disease. The median duration of 
response for those with an objective result was almost seven 
months with a range from 2.7 to greater than 46 months. 
A quality of life questionnaire showed a signiﬁ  cant difference 
in symptoms of the respondents with an improvement in the 
patients’ global skin assessment, generalized erythroderma, 
and pruritus. Approximately 68% of patients had a signiﬁ  cant 
clinical improvement of their pruritus. In addition, the use of 
rescue medications (topical steroids and oral anti-histamines) 
was decreased in those patients who responded. Importantly, 
32% of the patients who did not qualify as having an objective 
response had stable disease. Of these almost half had a 50% 
reduction of their lesions that lasted less than 6 weeks and, 
therefore, could not be qualiﬁ  ed as a partial response (Olsen 
et al 2001).
As in the prior studies using DAB486-IL-2 and 
DAB389IL-2, the presence of anti-DT and anti-DD 
antibodies were measured both at baseline and after each 
subsequent course. While a relatively minor proportion of 
patients had detectable levels of both anti-DT and anti-DD 
antibodies before treatment, in almost all patients these titers 
became positive and/or increased after treatment. There 
was no evidence that this rise in antibody titer impaired 
the response to treatment. Pharmacokinetic data seem to 
show more rapid clearance of DD by course 3, which may 
be related to signiﬁ  cant elevation in anti-DD antibodies in 
the majority of patients at around the same time. Additional 
data seem to suggest that this is probably a function of the 
individual antibody that is produced in each patient since no 
linear relationship was noted. Interestingly, elevated titers 
of anti-DD were actually associated with less elevation in 
liver transaminases, hypoalbuminemia, and development 
of a rash.
Toxicities and management
Adverse effects including hypersensitivity-like reactions 
occurred in the majority of patients especially after the 
ﬁ  rst infusion. In the study, 85% of patients complained 
of post-treatment ﬂ  u-like symptoms of mild to moderate 
severity. Other common adverse events included fever, 
chills, asthenia, arthralgia, headache, and myalgia, all of 
which appeared to be managed well with antipyretics. 
Gastrointestinal symptoms were also frequently seen. 
Various forms of a rash were also noted of mild to moderate 
severity that usually responded well to oral antihistamines 
and oral/topical steroids. Lymphopenia, the most common 
hematologic abnormality, was seen in approximately 70% of 
the patients. This abnormality was transient with a return to 
baseline levels usually within 2 weeks. While many patients 
suffered infectious complications, no causal relationship to 
treatment was identiﬁ  ed. It is important to note, premedication 
with steroids and anti-histamines were not permitted with 
this clinical trial. Consequently, the observed toxicities were 
expected to be more severe than those experienced by patients 
receiving effective premedication.
Again observed was the presence of a vascular-leak 
syndrome which the authors characterized by at least 2 of 
the following: anisarca, hypoalbuminemia, and hypotension. 
Based on this deﬁ  nition, it may have occurred in up to 25% 
of the patients. This number may be somewhat inﬂ  ated 
because the majority of the hypotensive events could have 
been attributed to hypersensitivity reactions rather than true 
vascular-leak syndrome. The vascular-leak syndrome was 
usually seen in the ﬁ  rst 14 days after receiving treatment 
and the majority of the patients who were re-treated did not 
have a recurrence. It was typically self-limiting and treatment 
with diuretics resulted in improvement. There was a slightly 
higher incidence of hypotension and hypoalbuminemia in the 
18 μg/kg/day dose group.
Considering the risk of vascular-leak syndrome with 
the lack of clear superior efﬁ  cacy with the higher dose, the 
authors suggested that the dose should be determined on a 
case- by-case basis. With these results, the US Food and Drug 
Administration approved the use of DD in patients with who 
have relapsed CTCL and are CD25 positive.
The signiﬁ  cant risk of both infusion related hypersensitivity 
reaction and the vascular leak syndrome was addressed in a 
small study of 15 patients with CTCL who received either 
dexamethasone or prednisone premedication (Foss et al 
2001). The incidence of acute hypersensitivity reaction 
and vascular leak syndrome was seen in 3 and 2 patients, 
respectively, all without compromising clinical response. 
There are also some limited data to suggest that steroid 
pre-medication may induce expression of CD25 on T-cells 
and this correlated with increased response rate (Duvic 2006). 
Denileukin diftitox can be administered in the outpatient 
setting via a peripheral line. Pre-medication protocols usually 
consist of dexamethasone 4 mg iv, diphenyhydramine 
25 to 50 mg iv, and acetaminophen 650 mg po (Dang et al 
2007). Following infusion, adequate saline hydration should Biologics: Targets & Therapy 2008:2(4) 722
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continue since this has also shown to diminish the incidence 
of vascular leak syndrome (Duvic 2006).
Since receiving FDA approval there have been case 
reports of thyrotoxicosis related to DD administration 
(Ghori et al 2006). Eight patients with mycosis fungoides 
receiving either 9 or 18 μg/kg/day for 5 days every 3 weeks 
developed tremors, tachycardia, nausea, diarrhea, and 
weight loss. Clinical hyperthyroidism usually developed 
by the time of the second cycle of treatment. Many of 
these symptoms were initially related to side effects from 
this medication. Discontinuation of DD caused resolution 
of the thyrotoxicosis. Five of the patients later developed 
long-standing hypothyroidism requiring thyroid replacement 
therapy. There have also been some limited case reports of 
DD associated retinopathy; however, the true incidence of 
this event or its mechanism have not been rigorously studied 
(Ruddle et al 2006).
Combination therapies
With clear treatment efﬁ  cacy exhibited by DD in patients 
with CTCL, many groups explored ways to improve 
on its treatment effects. Shao and colleagues addressed 
modiﬁ  cation of tumor cells so that they can express high 
and intermediate afﬁ  nity IL-2 receptors and therefore have a 
greater cytotoxic effect after DD exposure (Shao et al 2002). 
Arginine butyrate, a histone deacetylase (HDAC) inhibitor, 
was shown to increase IL-2Rβ gene expression and resulting 
p 75 (CD122) presence. Cells exposed to this compound and 
DD showed a clear increase in cell death.
This observation of in vitro synergy between DD is of 
particular interest since vorinostat, another HDAC inhibitor, 
has been approved by the FDA for the treatment of CTCL. 
This ﬁ  nding provides a rationale for combination therapy 
with DD and vorinostat or other HDAC inhibitors in the 
treatment of CTCL.
Gorgun and Foss investigated the role of the rexinoids 
bexarotene (Targretin®) and alitretinoin (Panretin®) as 
modulators of high affinity IL-2R expression (Gorgun 
and Foss 2002). Bexarotene has been used as a standard 
treatment for patients with early and advanced stage CTCL. 
These compounds are ligands that bind to members of the 
retinoic acid receptor family including RAR, RXR, PPAR, 
and VDR. Bexarotene binds to the retinoic X receptor (RXR) 
while alitretinoin binds to the retinoic acid receptor and 
RXR. Once bound, transcription of genes involved in cell 
growth, differentiation, and apoptosis can occur. Rexinoids 
have immunomodulatory function and have been shown 
to increase IL-2 receptor expression on T-cells. This study 
showed that both bexarotene and alitretinoin increased the 
expression of CD25 (p 55) and CD75 (p 75) in CTCL cell 
line. Cells that were subsequently exposed to DD showed a 
50% to 70% decrease in protein synthesis. This observation 
suggests that increases in expression of components of the 
IL-2R can be achieved by retinoids and rexinoids, and that 
may enhance the cytotoxicity of DD.
A phase I trial investigating the use of bexarotene in 
conjunction with DD in patients with relapsed or refractory 
CTCL was undertaken. In this dose-escalating trial bexarotene 
at doses of 75 to 300 mg/day was combined with DD at a 
dose of 18 μg/kg/day × 3 every 21 days. Of the 12 evaluable 
patients, there was a 67% response rate, 4 patients exhibiting 
a complete response and another 4 showing a partial response 
(Foss et al 2005). CD25 expression on circulating CD4+ cells 
after bexarotene treatment was compared with baseline levels. 
Of the 12 patients, 8 showed greater than 50% increase in 
CD25 expression. This included all 4 patients with a complete 
response and 1 patient with a partial response. The effect on 
the IL-2R expression occurred at a relatively low dose of 
bexarotene of 150 mg/day. There was also some evidence 
of increased CD25 expression by a normal population of 
CD4+ cells. Although bexarotene increased expression 
of CD25, the authors concluded that because a relatively 
small sample size no deﬁ  nitive relationship could be made 
between an objective clinical response and upregulation of 
CD25 expression. In addition, bexarotene may act as a potent 
immunomodulator and possibly play a role in the cytotoxic 
effect of this combination, although not via this proposed 
mechanism. Hypertriglyceridemia and hypothyroidism were 
seen, which was attributed to bexarotene and occurred at a 
similar incidence as in prior studies of this medication. The 
incidence of grade 3 or 4 lymphopenia was seen in 57% of the 
all patients enrolled; this rate is considerably higher than that 
seen in prior trials of either bexarotene or DD as single agents. 
Although suggestive of a synergistic effect, this relationship 
is not clear, since the majority of the patients at baseline had 
some element of lymphopenia. Regardless as to the cause, 
this abnormality resolved shortly after discontinuation of the 
medications, and there were no adverse effects attributed to 
opportunistic infections.
Recently, Negro-Vilar and colleagues presented a 
meta-analysis analyzing the efﬁ  cacy and safety of DD in 3 
phase III clinical trials (Negro-Vilar et al 2008). The data 
indicate that both the 9 and 18 μg/kg iv daily dose regimen 
for 5 days, every 28 days, showed a signiﬁ  cant overall 
response rate, progression-free survival, and progression 
of disease when compared to placebo. In addition, there Biologics: Targets & Therapy 2008:2(4) 723
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was no correlation between CD25 expression and response. 
Adverse events were generally mild to moderate with a few 
more severe events seen in the treatment group. The toxicity 
of treatment resolved to placebo levels after the second or 
third course of treatment.
Conclusion
Some 20 years have elapsed since the initial work on a 
diphtheria fusion toxin. In that time, clinical trials of DD 
in CTCL have shown significant efficacy against this 
disease. This has correlated to better outcomes and overall 
improvement in quality of life for many patients. The 
clinical trials cited in this paper demonstrate that DD has a 
measurable response rate of ∼30% to 40% in patients with 
CTCL, and that these responses are seen in heavily pre-treated 
patients with all stages of this disease. In addition, in some 
patients the duration of the response is prolonged. However, 
several clinical and laboratory observations have proven to 
be impediments to a wider use of this compound. First, the 
identiﬁ  cation of the subset patients with CTCL who beneﬁ  t 
from this agent is difﬁ  cult, as the biologic markers which 
might predict response (CD25 expression) or non-response 
(presence of anti DT or IL-2 antibodies) do not correlate with 
the clinical outcomes. Second, the concern over treatment-
related toxicity and the currently recommended dose schedule 
make treatment with drug unattractive, particularly to 
physicians who have limited experience in the treatment of 
CTCL. Finally, the introduction of bexarotene and vorinostat, 
both oral agents with similar response rates and durations of 
response to DD, has shifted the intravenous drug to a lower 
position in the hierarchy of CTCL treatments.
These difﬁ  culties, however, provide an opportunity for 
additional investigation in the use of DD. First, the development 
of more reliable reagents which permit the accurate 
identiﬁ  cation of the high, low and intermediate afﬁ  nity IL-2R 
will allow for the sub-classiﬁ  cation of patients with CTCL 
(or other IL-2R expressing malignancies). Second, a more 
general appreciation of the pre-medication regimens which 
reduce infusion-related toxicity and the vascular leak syndrome 
should encourage the wider use of DD in CTCL. Finally, the 
availability of 3 distinct classes of medications (rexinoids, DD, 
and HDAC inhibitors) with unique mechanisms of actions and 
non-overlapping toxicities provides many opportunities to 
investigate combinations of these drugs and to identify more 
tolerable and effective therapy.
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